Find out how the Opto CLD workflow sets a new standard for quality, capacity, and speed in cell line development to let BioPharma get more molecules to the clinic faster.
Download FilePhilip Tagari, VP Therapeutic Discovery, Amgen, discusses how the Berkeley Lights’ platform has transformed the way Amgen approaches antibody discovery and cell line development.
Overview of the Opto CLD 2.0 workflow and representative results.
Read this application note to learn more about how to get early, multi-parameter assessment of clones with the Opto Assure assay series.